1 King William Street

London EC4N 7AF


Tel:  0203-858-8185

Fax: 0203-858-8188

  • GBX Events
  • Gbx Events (Summit) You Tube
  • Gbx Events (Summit) Twitter

© 2019 by GBX. Proudly created with GBX Events Ltd.
Company Number: 11782795 - VAT: 317674779 UK

Cell & Gene Therapy Innovation Speakers 

Laura Sepp-Lorenzino

Chief Scientific Officer

Laura Sepp-Lorenzino, Ph.D. is Chief Scientific Officer of Intellia Therapeutics. In this role, she oversees all drug research across in vivo and ex vivo (engineered cell therapy) areas.

Intellia Therapeutics

Christian van den Bos

Managing Director

Dr. van den Bos current developed technology and IP dramatically enhancing the efficacy of mesenchymal stem cells (MSCs), the productivity of cell culture media for primary cells and a novel drug target for anti-inflammatories.

Mares Ltd

Rob Allen


Rob is a project leader in the biopharmaceutical industry with broad understanding of cell therapies and biologics development.

Dark Horse Consulting Group

Otto-Wilhelm MERTEN

Gene Therapy and Vector Manufacturing Specialist

Otto-Wilhelm MERTEN has a degree in biotechnology (Ph.D.) from the University of Life Sciences in Vienna (Inst. of Applied Microbiology, Prof. H. Katinger), holds an HDR at the University of Evry/Val-d’Essonne and is Visiting Professor at ITQB/UNL in Lisbon.

Miltenyi Biotec SAS

Jennifer murray

Managing Director/Past Chair

Jenny has over 30 years’ experience in the cell culture industry in the UK and worldwide and a track record in building successful SMCs. Jenny is the current owner of Life Science Group Ltd (LSG).

Life Science Group Ltd/ International Serum Industry Association

Emanuele Ostuni

Head of Europe, Cell and Gene Therapy

Emanuele is Head of Europe for Cell and Gene Therapies at Novartis Oncology, where he oversees the commercialization of this portfolio in Europe. Emanuele is with Novartis since 2012.

Novartis Pharma AG

Ohad Karnieli

Founder and CEO

Dr. Karnieli earned his PhD in Biotechnology focusing on Cell & Gene Therapy from the Sacler school of Medicine at Tel Aviv University and an MBA from the Haifa University school of management.

Adva Biotechnology

Eric Halioua

President & Chief Executive Officer

Mr. Eric Halioua, MS, MBA, serves as President of the Board, Chief Executive Officer and President of PDC line Pharma SAS.

PDC*line Pharma

Martin Pohle

Branch Manager Berlin​

Martin Pohle is a in industry expert and manager in specialty logistics for Pharmaceutics, Semiconductor, Automotive and the Life Sciences.


Yen Choo

Executive Chairman

Dr Choo is Executive Chairman of Plasticell Ltd and Chief Executive of Progenitor Labs Ltd. He is the founder of Plasticell and served as Chief Executive and Chief Scientist of the company.


Magdalena Tary-Lehmann

Chief Scientific Officer

Magdalena Tary-Lehmann is a Co-Founding Scientist and Chief Scientific Officer for Cellular Technology Limited (CTL) and Adjunct Associate Professor of Case Western Reserve University (CASE) Department of Pathology.

Cellular Technology Limited

Houria Bachtarzi

Senior Consultant, Regulatory Affairs – Gene and Cell Therapies

Dr Houria Bachtarzi is a Senior Consultant, Regulatory Affairs - Gene and Cell Therapies, with a strong scientific and regulatory experience in the field of advanced biological therapies including virally vectored gene therapy

NDA Group AB

Kai Wilkens

Senior Director Sales & Marketing

Dr. Kai Wilkens completed his Biology studies and PhD thesis in Molecular Biology in Bochum working in the field of Gene Expression Control.

Advanced Cell Diagnostics, Inc.

Stephen Hyde

Co-Director of the Gene Medicine Research Group

As Co-Director of the Gene Medicine Research Group his research is focused on the application of gene therapy technologies to provide therapeutic interventions for human disease.

University of Oxford ​

Marc Van Dijk

Vice President Platform Technology

Marc van Dijk, Ph.D. leads platform development for AgenTus and Agenus, and heads the Agenus UK site.

AgenTus Therapeutics Ltd

Kyle Grant

Associate Director of Vector Production

I am a classically trained chemical engineer with a deep understanding of molecular biology. My doctoral work focused on molecular virology with an emphasis on developing scalable technology for viral based gene therapy modalities.


Darrin Disley

Chief Executive Officer

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown or invested in over 40 start-up life science, technology and social enterprises.

Mogrify Ltd

Annie Hubert

Senior Director of European Public Policy

Annie brings over 30 years of experience in European regulatory and government affairs, pricing, reimbursement and market access to the ARM Team.

Alliance for Regenerative Medicine

Shibashish Giri

Deputy Head, Applied Stem Cell Biology and Cell Technology 

Dr. Shibashish Giri is a stem cell specialist in research and therapy. He has more than 12 years’ experience in preclinical research and clinical therapy for cell, tissue and organ regeneration in Germany.

University of Leipzig

Sandy Macrae


Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016.


Katherine Seidl

Director, Oncology

Dr. Katherine Seidl earned a Ph.D. in Genetics (1996) from Stanford University, under the supervision of Drs. Len and Lee Herzenberg studying B cell development and immunoglobulin repertoire.

Bluebird Bio

Todd McAllister

Executive Director

Dr. McAllister is the Executive Director at the Amnion Foundation, a public stem cell bank that is developing technology pioneered by Dr. Anthony Atala at Mass General Hospital in Boston (www.amnionfoundation.org).

Amnion Foundation

Stefan Glück

Vice President, Global Medical Affairs

Stefan Glück, MD, PhD, is V.P of Global Medical Affairs, at Celgene Corporation since October 2014, and a medical oncologist with focus on breast cancer.

Celgene Therapeutics

Sandra van Wetering

Chief Operations Officer

Sandra van Wetering is an expert in the development and manufacturing of cell-based products, and has in-depth knowledge the regulatory strategies and processes involved in development of such products,


Michael Kapinsky

Strategic Marketing Manager

Michael Kapinsky is a chemist by training.

Beckman Coulter

Fabien Dorange

Head of Analytical Development

​Dr Ryan Cawood is the CEO and founder of Oxford Genetics, a UK synthetic biology company that generates scalable solutions for the manufacture of viral vectors.


Franz Gerner

Sr. Director, Technical Innovation and New Technologies

Franz has been working in the Gene Therapy field for more than 20 years, optimizing the manufacturing and of adeno associated viral vectors.


Richard Harbottle

Head of DNA Vector Research Group

Dr Richard Harbottle is currently an Independent Group Leader of Gene Therapy Research in the section of Molecular Medicine at Deutsches Krebsforschungszentrum (DKFZ).

German Cancer Research Centre

Ryan Cawood

CEO and Founder

Dr Ryan Cawood is the CEO and founder of Oxford Genetics, a UK synthetic biology company that generates scalable solutions for the manufacture of viral vectors.

Oxford Genetics

Dominic Clark

Global Head of Cell Therapy

Passionate, dedicated market strategy and business development industry leader with a team driven collaborative approach.

HemaCare Corporation

André G. Gerth

Chief Executive Officer

Following his PhD in 1991, he worked as a managing partner in several biotechnology companies in Germany. Today he acts as Chief executive Officer Director of BioPlanta GmbH and FamiCord Deutschland GmbH.

BioPlanta GmbH

Pamela Tranter

Head, Translational Research Group

Pamela joined UCL Translational Research Office (TRO) in 2014 and has been leading the Translational Research group since 2016.


Maria Papathanasiou

Research Associate

Dr Maria Papathanasiou is an appointed Lecturer at the Department of Chemical Engineering, Imperial College London (in effect April 2020).

Imperial College London

Lior Raviv

Vice President Development

Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development.

Pluristem Therapeutics

Jean-Pierre Latere

Chief Operating Officer

Jean-Pierre joined Celyad in January 2016 and is responsible for strengthening the organization and key processes in manufacturing, quality, program management, clinical operations and regulatory affairs

Celyad SA

Namir Hassan


Namir Hassan joined Zelluna Immunotherapy in August 2018 to serve as Chief Scientific Officer.

Zelluna Immunotherapy

Tanvir Tabish

Head of Formulation Development & Characterisation

Tanvir joined Shire about three years ago and is presently the Head of Formulation Development and Characterisation


Ajan Reginald


Ajan Reginald is a Biotech entrepreneur and the co-founder and Chief Executive of Celixir plc. Celixir plc is a British cellular medicines company with drugs in late-stage clinical trials for heart failure and tendon repair and an extensive in-house product pipeline.


John Bridgeman

Director of Cell Therapy Research

John undertook his PhD in 2004 under the supervision of Dr. David Gilham and Prof. Robert Hawkins at the University of Manchester.

Cellular Therapeutics

Alain Vertès

Managing Director

Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment.

NxR Biotechnologies GmbH

Mio Muelthaler

Director, Business Development, Europe

Mio Muelthaler is on a mission to spread the news about a new fascinating disruptive nanofluidics based single-cell technology for gene therapy in EU.

Berkeley Lights

Marina Feschenko

Principal Scientist

Dr. Marina Feschenko is currently a Principle Scientist at Biogen. She has been with the company for 7.5 years.


Bryan Deane

Head Of Product & Process Innovation

After graduating in Pharmacology and completing a PhD in Neuropathology, Bryan embarked on a long and successful career in the pharmaceutical industry

Association Of The British Pharmaceutical Industry

Paula Maria M. Alves


Paula M Alves graduated in Biochemistry at the Faculdade de Ciências da Universidade de Lisboa, and holds a PhD in Biochemical Engineering from Instituto de Tecnologia Química Biológica da Universidade Nova de Lisboa.